Healthcare systems provider Tabula Rasa Healthcare has acquired SinfoníaRx, a US-based medication therapy management spinout from University of Arizona, for an undisclosed sum.
The deal has provided an exit to the university’s commercialisation arm, Tech Launch Arizona..
SinfoníaRx was formed in 2006 and offers medication therapy management (MTM) systems that collate and analyse data from prescriptions to flag up any risk of drugs interacting with each other, while also encouraging greater value and patient discipline.
The system is based on research by SinfoníaRx president Kevin Boesen, who developed the technology at the College of Pharmacy before SinfoníaRx licensed it from commercialisation arm Tech Launch Arizona in 2013.
Tabula Rasa hopes SinfoníaRx will strengthen its own healthcare platform with better access to key MTM markets in the US such as commercial payers and self-funded employers.
Annual turnover at SinfoníaRx reached $27.1m during 2016, and is expected to grow to $31m this year. Its services now help 50 million patients in the US and the company made 1.1 million suggestions for improving drug schedules throughout last year.
David Allen, vice-president at University of Arizona, said: “We are delighted for all the parties involved in this transaction.
“This was one of the first licences undertaken by the then-new Tech Launch Arizona, and through a multiparty structured auction approach we were able to identify the best team to develop the market and build value by working with University of Arizona.”
